Nutriband Inc. Pioneers Abuse-Deterrent Technology with Aversa(TM) Fentanyl Patch

Nutriband Inc. (NASDAQ: NTRB) is making strides in the pharmaceutical industry with its development of Aversa(TM), a proprietary abuse-deterrent transdermal technology. This innovation is specifically designed to address the critical challenges of diversion, misuse, abuse, and accidental exposure associated with potent opioids like fentanyl. With fentanyl being approximately 50 times more potent than heroin, the development of safe and effective delivery systems is paramount. Nutriband's Aversa(TM) fentanyl patch represents a significant advancement in this field, with an estimated market potential of $80 million to $200 million annually within five years of launch.

The importance of Nutriband's work cannot be overstated. The opioid crisis has highlighted the urgent need for technologies that can prevent the misuse of these powerful medications while ensuring they remain accessible to patients who genuinely need them. By focusing on transdermal technologies, Nutriband is at the forefront of creating solutions that balance patient access with the imperative to mitigate abuse. This dual focus not only addresses a pressing public health issue but also opens up substantial commercial opportunities for the company.

For investors and stakeholders interested in following Nutriband's progress, the latest news and updates are available in the company’s newsroom at https://ibn.fm/NTRB. The development of Aversa(TM) and similar technologies is a testament to the innovative approaches being taken to tackle some of the most challenging issues in healthcare today. As Nutriband continues to advance its abuse-deterrent technologies, the implications for patient safety, public health, and the pharmaceutical industry are profound.